West Pharmaceutical Services Inc. (WST) News

West Pharmaceutical Services Inc. (WST): $375.35

3.31 (+0.89%)

POWR Rating

Component Grades

Momentum

F

Stability

B

Sentiment

Quality

B

Filter WST News Items

WST News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

WST News Highlights

  • For WST, its 30 day story count is now at 3.
  • Over the past 23 days, the trend for WST's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about WST are DRUG, WEST and MMSI.

Latest WST News From Around the Web

Below are the latest news stories about WEST PHARMACEUTICAL SERVICES INC that investors may wish to consider to help them evaluate WST as an investment opportunity.

MMSI or WST: Which Is the Better Value Stock Right Now?

MMSI vs. WST: Which Stock Is the Better Value Option?

Yahoo | December 28, 2023

West Announces First-Quarter 2024 Dividend

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2024 dividend of $0.20 per share. The dividend will be paid on February 7, 2024, to shareholders of record as of January 31, 2024.

Yahoo | December 6, 2023

West Pharmaceutical's (WST) New Launch to Expand Portfolio

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Yahoo | December 5, 2023

West Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.

Yahoo | December 4, 2023

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Yahoo | November 29, 2023

13 Best Dividend Stocks with Upside Potential

In this article, we discuss 13 best dividend stocks with upside potential. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Dividend Stocks with Upside Potential. Pivotal Advisors’ CEO, Tiffany McGhee, discussed the importance of dividend stocks in today’s market in her […]

Yahoo | November 19, 2023

Blue-Chip Bargains: Top 3 Oversold Aristocrats for Value Investors

These three oversold dividend aristocrats offer growth and long-term income while the stocks trade at attractive levels.

Rick Orford on InvestorPlace | November 15, 2023

Sotera Health Appoints Karen Flynn to Board of Directors

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recen

Yahoo | November 13, 2023

West Pharmaceutical Services Appoints Nilesh Shah as Vice President and General Manager of Emerging Markets

West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today announced it has appointed Nilesh Shah to serve as Vice President and General Manager of Emerging Markets, based in Singapore. Overseeing the Asia Pacific and South America regions, Nilesh will be responsible for growing West's presence and leadership in these markets.

Yahoo | November 9, 2023

Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes

Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.

Yahoo | November 3, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!